Molecular Partners (MOLN) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Molecular Partners and Orano Med have expanded their co-development agreement to create four Radio-DARPin programs, with each company securing commercialization rights to two. The strengthened collaboration aims at advancing targeted cancer therapies, with first-in-human studies expected to begin in 2025. Despite the expansion, Molecular Partners anticipates no immediate financial impact for 2024 and maintains a strong cash position.
For further insights into MOLN stock, check out TipRanks’ Stock Analysis page.